切换至 "中华医学电子期刊资源库"

中华老年病研究电子杂志 ›› 2020, Vol. 07 ›› Issue (02) : 12 -16. doi: 10.3877/cma.j.issn.2095-8757.2020.02.004

所属专题: 专题评论 文献

论著

血清生长分化因子-15、可溶性人基质裂解素2、半乳糖凝集素-3检测在老年心力衰竭严重程度和预后评估中的应用
吴桂颖1, 胡立群1,(), 李红旗1   
  1. 1. 230001 合肥,中国科学技术大学附属第一医院老年心内科
  • 收稿日期:2019-12-09 出版日期:2020-05-28
  • 通信作者: 胡立群
  • 基金资助:
    安徽省心血管病研究所科研项目(KF2018002)

Application of detection of serum growth differentiation factor-15, soluble human stromalysin 2 and galectin-3 on the severity and prognosis evaluation in elderly patients with heart failure

Guiying Wu1, Liqun Hu1,(), Hongqi Li1   

  1. 1. Geriatric Department of Cardiology, The First Affiliated Hospital of USTC, Hefei 230001, China
  • Received:2019-12-09 Published:2020-05-28
  • Corresponding author: Liqun Hu
  • About author:
    Corresponding author: Hu Liqun, Email:
引用本文:

吴桂颖, 胡立群, 李红旗. 血清生长分化因子-15、可溶性人基质裂解素2、半乳糖凝集素-3检测在老年心力衰竭严重程度和预后评估中的应用[J/OL]. 中华老年病研究电子杂志, 2020, 07(02): 12-16.

Guiying Wu, Liqun Hu, Hongqi Li. Application of detection of serum growth differentiation factor-15, soluble human stromalysin 2 and galectin-3 on the severity and prognosis evaluation in elderly patients with heart failure[J/OL]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(02): 12-16.

目的

探讨血清生长分化因子-15(growth differentiation factor-15, GDF-15)、可溶性人基质裂解素2(soluble suppression of tumorigenicity 2, sST2)及半乳糖凝集素-3(galectin-3, Gal-3)水平对老年心力衰竭患者病情严重程度与预后的评估价值。

方法

选取中国科学技术大学附属第一医院2018年1~8月收治的老年心力衰竭患者74例,根据随访1年后的不良事件结局(心血管死亡或因心力衰竭再住院)分为事件组和无事件组,先行两组患者的单因素比较(计量资料采用t检验或秩和检验,计数资料比较采用χ2检验),再将有意义的指标纳入多因素COX回归分析,并采用ROC曲线评价GDF-15、sST2和Gal-3的检测价值。

结果

随访期间发生不良事件者28例(事件组),未发生不良事件46例(无事件组)。单因素分析显示,事件组患者血清GDF-15、Gal-3、sST2水平均显著高于无事件组(t=4.880、3.325,z=-4.213;P<0.05)。GDF-15、sST2、Gal-3水平与N末端B型利钠肽前体水平和NYHA心功能分级均呈正相关(r=0.647、0.706、0.471,0.668、0.603、0.446;P<0.05),GDF-15、sST2水平与左心室舒张末期内径呈正相关(r=0.322、0.289,P<0.05或0.01)、与左心室射血分数呈负相关(r=-0.262、-0.481,P<0.05)。COX回归分析显示,sST2是老年心力衰竭患者1年内不良事件的独立危险因素(OR=1.032,95%CI=1.009-1.054,P<0.01)。ROC曲线结果显示,血清GDF-15、sST2和Gal-3联合检测的曲线下面积最高,为0.851(95%CI=0.763-0.937)。

结论

血清GDF-15、sST2和Gal-3水平可以反映老年心力衰竭患者的病情严重程度,具有一定的预后价值,三者联合检测的效果最优。

Objective

To investigate the levels of serum growth differentiation factor-15 (GDF-15), soluble human stromalysin 2 (sST2) and galectin-3 (Gal-3) in evaluating the severity and prognosis of elderly patients with heart failure.

Methods

74 elderly patients with heart failure who were hospitalized in the First Affiliated Hospital of USTC from January 2018 to August 2018 were selected. According to the outcome of adverse events (cardiovascular death or rehospitalization due to heart failure) after 1 year of follow-up, they were divided into the event group and the event-free group. Univariate comparison was used between the two groups (the measurement data were tested by t test or rank sum test, while the count data were tested by chi-square test). Then, meaningful indicators were included in multivariate COX regression analysis. The characteristic curve (ROC) evaluates the prognostic value of combined detection of GDF-15, sST2, and Gal-3 in elderly patients with heart failure.

Results

During the follow-up period, 28 adverse events occurred (event group), no adverse events occurred in 46 cases(non-event group). GDF-15, sST2, and Gal-3 were significantly higher in the event group than in the non-event group (t=4.880, 3.325, z=-4.213, P < 0.05). Correlation analysis showed that GDF-15, sST2, Gal-3 were positively correlated with N-terminal B-type natriuretic peptide and NYHA cardiac function grades (r=0.647, 0.706, 0.471, 0.668, 0.603, 0.446, P < 0.05), GDF-15 and sST2 were positively correlated with left ventricular end-diastolic inner diameter (r=0.322, 0.289, P < 0.05), and negatively correlated with left ventricular ejection fraction (LVEF) (r=-0.262, -0.481, P < 0.05). Multivariate COX regression analysis showed that sST2 was the risk factor for adverse events in elderly patients with heart failure within one year (OR=1.032, 95%CI=1.009-1.054, P < 0.05). ROC curve results showed that the area under the curve of serum GDF-15, sST2 and Gal-3 combined detection was the highest, which was 0.851 (95%CI=0.763-0.937).

Conclusion

Serum GDF-15, sST2 and Gal-3 levels can reflect the severity of the disease in elderly patients with heart failure, and have certain prognostic value.

表1 两组患者一般资料的比较
指标 事件组(28例) 无事件组(46例) 检验值 P
年龄(岁) 72.9±7.8 71.5±6.6 t=0.855 >0.05
男性[例(%)] 15(53.6) 25(54.3) χ2=0.004 >0.05
收缩压(mmHg) 119.4±13.2 127.8±15.6 t=1.993 <0.05
舒张压(mmHg) 77.5±10.8 80.1±12.8 t=0.907 >0.05
心率(次/min) 72.5±6.1 75.1±7.9 t=0.897 >0.05
BMI(kg/m2 23.2±2.9 22.6±3.4 t=0.751 >0.05
NYHA心功能分级[例(%)] ? ? ? ?
? Ⅱ级 4(14.3) 26(56.5) χ2=11.188 <0.01
? Ⅲ级 13(46.4) 17(37.0) χ2=4.150 <0.05
? Ⅳ级 11(39.3) 3(6.5) χ2=10.138 <0.01
既往合并症[例(%)] ? ? ? ?
? 心肌梗死 9(32.1) 11(23.9) χ2=0.598 >0.05
? 高血压 12(42.9) 21(45.7) χ2=0.055 >0.05
? 心房颤动 8(28.6) 12(26.1) χ2=0.054 >0.05
? 脑卒中 7(25.0) 11(23.9) χ2=0.080 >0.05
? 糖尿病 12(42.9) 14(30.4) χ2=1.179 >0.05
血钠(mmol/L) 135.3±6.4 137.5±4.1 t=0.986 >0.05
eGFR(ml·min-1·1.73-1 79.7±25.7 95.3±23.8 t=-2.647 <0.05
空腹血糖(mmol/L) 5.09±0.76 5.12±0.87 t=0.526 >0.05
血红蛋白(g/L) 129.7±11.4 132.3±12.8 t=0.526 >0.05
LDL-C(mmol/L) 2.2±1.1 2.4±1.0 t=-0.878 >0.05
NT-proBNP(pg/ml) 6096.5(3812.5,12975.0) 2179.0(996.5,3910.0) z=-4.999 <0.01
GDF-15(pg/ml) 546.4±249.5 311.0±165.7 t=4.880 <0.01
sST2(ng/ml) 22.3(14.1,34.0) 12.6(9.4,16.0) z=-4.213 <0.01
Gal-3(ng/ml) 25.0±15.6 14.7±6.0 t=3.325 <0.01
LVEF(%) 50.3±11.8 56.4±10.9 χ2=-2.278 <0.05
LVEDD(mm) 58.2±8.6 52.8±6.6 t=3.041 <0.01
6 min步行试验(m) 221.7±141.7 399.4±173.3 t=-4.569 <0.01
表2 74例心力衰竭患者GDF-15、sST2、Gal-3与心功能指标的相关性
表3 心力衰竭预后不良的危险因素分析
图1 GDF-15、sST2、Gal-3检测的ROC曲线分析
[1]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart failure society of America[J]. J Am Coll Cardiol, 2017, 70(6):776-803.
[2]
Mair J, Gerda F, Renate H, et al. Hea-dto-head comparison of B-type natriuretic peptide (BNP) and NTproBNP in daily clinical practice[J]. Int J Cardiol, 2008, 124(2):244-246.
[3]
Olechnicki M, Kasprzak K, Goch A. Growth differentiation factor 15--a new marker in heart diseases[J]. Pol Merkur Lekarski, 2010, 28(168):470-472.
[4]
Dalal JJ, Digrajkar A, Das B, et al. ST2 elevation in heart failure, predictive of a high early mortality[J]. Indian Heart J, 2018, 70(6):822-827.
[5]
Henderson NC, Sethi T. The regulation of inflammation by galectin-3[J]. Immunol Rev, 2009, 230(1):160-171.
[6]
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.
[7]
Di Lenarda A, Scherillo M, Maggioni AP, et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of words. The temistocle study[J]. Am Heart J, 2003, 146(4):E12.
[8]
Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis[J]. Nat Med, 1999, 5(11):1313-1316.
[9]
Sharma A, Stevens SR, Lucas J, et al. Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure[J]. JACC, Heart Fail, 2017, 5(10):724-734.
[10]
Chan MM, Santhanakrishnan R, Chong JP, et al. Growth differentiation factor 15 in heart failure with preserved vs reduced ejection fraction[J]. Eur J Heart Fail, 2016, 18(1):81-88.
[11]
Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J]. J Clin Invest, 2007, 117(6):1538-1549.
[12]
Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis[J]. JACC Heart Fail, 2017, 5(4):280-286.
[13]
Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure clinical perspective: Results from the HF-ACTION study[J]. Circ Heart Fail, 2015, 5(1):72-78.
[14]
Zhang T, Shao B, Liu GA. Research on clinical value of galectin-3 in evaluating the prognosis of acute heart failure[J]. Eur Rev Med Pharmacol Sci, 2017, 21(19):4406-4410.
[15]
Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community[J]. J Am Coll Cardiol, 2012, 60(14):1249-1256.
[16]
Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure[J]. Circ Heart Fail, 2012, 5(2):183-190.
[17]
李祥东,袁婷,王俊,等.联合检测血清半乳糖凝集素-3、可溶性生长刺激表达基因2蛋白在慢性心力衰竭患者中的应用价值[J].临床心血管病杂志,2018,34(9):914-917.
[18]
Grande D, Leone M, Rizzo C, et al. A multiparametric approach based on NT-proBNP, ST2, and Galectin3 for stratifying one year prognosis of chronic heart failure outpatients[J]. J Cardiovasc Dev Dis, 2017, 4(3):9.
[19]
Hage C, Michaëlsson E, Linde C, et al. Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: A holistic proteomic approach[J]. Circ Cardiovasc Genet, 2017, 10(1):e00163.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[7] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[8] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[9] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[10] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[11] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[13] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要